Bionano Genomics (BNGO) EBITDA Margin (2017 - 2026)

Bionano Genomics has disclosed EBITDA Margin across 10 years of filings, most recently posting 107.63% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 107.63%, up 1263.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 111.6% (down 11104.0% YoY), and the FY2025 annual result was 107.83%, down 4051.0% from the prior year.
• EBITDA Margin came in at 107.63% for Q1 2026 at Bionano Genomics, roughly flat from 107.36% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 839.46% in Q4 2024 to a low of 1214.98% in Q3 2023.
• The 5-year median for EBITDA Margin is 354.92% (2024), against an average of 314.36%.
• Across the five-year window, EBITDA Margin surged 107221 bps in 2024 and slumped 94682 bps in 2025, its largest moves.
• Bionano Genomics' EBITDA Margin stood at 456.81% in 2022, then surged by 49 bps to 232.75% in 2023, then jumped by 461 bps to 839.46% in 2024, then sank by 113 bps to 107.36% in 2025, then fell by 0 bps to 107.63% in 2026.
• The last three EBITDA Margin figures came in at 107.63% (Q1 2026), 107.36% (Q4 2025), and 115.9% (Q3 2025), per Business Quant data.